Steven Fishbane on Muck Rack

Steven Fishbane

Cold Spring Harbor
As seen in: Wiley Online Library, BMJ Open, Frontiers, Medscape, The New England Journal of Medicine, MedCity News, Healio, Journal of the American Society of Nephrology (JASN), ASN Journals, EMJ- European Medical Journal and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Steven

Contact Steven, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Frontiers | Commentary: Efficacy and safety of HSK21542 for pruritus management in hemodialysis patients: a multicenter, randomized, double-blind, placebo-controlled trial

|
By Steven Fishbane
| Frontiers
Introduction I read with interest the article by Pan et al. (2025) on HSK21542 (Anrikefon) for managing CKD-associated pruritus (CKD-aP) in haemodialysis patients. This Phase II trial addresses an important unmet need for patients that suffer from CKD-aP. However, I have identified material errors in the authors’ interpretation of their results, as well as some uncontextualized comparisons. Here I highlight these, in the interest of scientific dialogue.
Open in Who Shared Issue with article?

The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis

|
By Steven Fishbane
| kidney-international.org
Keywords cardiovascular disease chronic kidney disease hemodialysis People with kidney failure who undergo regular hemodialysis can experience both high and low blood potassium (K+) concentrations, which may cause sudden death and heart rhythm disorders.
Open in Who Shared Issue with article?

A phase 3b, multicenter, open‐label, single‐arm study of roxadustat (ASPEN): Operational learnings within United States dialysis organizations

|
By Steven Fishbane, Mark Vishnepolsky, Yemmie Oluwatosin, Jacqueline Nolen
| Wiley Online Library
Endpoints The primary efficacy endpoints were the proportion of patients with mean Hb ≥10 g/dL, averaged over weeks 16–24, and the mean Hb change from baseline to the average over weeks 16–24. Pre-specified subgroup analyses were performed by sex, age group, race, baseline Hb categories, baseline iron status, cardiovascular/cerebrovascular/thromboembolic medical history, starting dose, participating dialysis organizations, and baseline ESA dose category.
Open in Who Shared Issue with article?
See all 20 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Steven

Contact Steven, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified